3:I[2885,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-6cc98b9fe15a622c.js"],"default"]
4:I[231,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-6cc98b9fe15a622c.js"],""]
5:I[9275,[],""]
7:I[1343,[],""]
8:I[8173,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","185","static/chunks/app/layout-24f8abeacb8025a3.js"],"Image"]
9:I[5864,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","185","static/chunks/app/layout-24f8abeacb8025a3.js"],"default"]
2:T5bd,{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does CU6 do?","acceptedAnswer":{"@type":"Answer","text":"Clarity Pharmaceuticals (CU6) is an Australian biotech company developing a new generation of diagnostic and therapeutic radiopharmaceuticals for cancer. They use copper isotopes (Copper-64 for imaging, Copper-67 for therapy) to target specific cancer cells, aiming for more precise and effective cancer treatment."}},{"@type":"Question","name":"Is CU6 a good investment?","acceptedAnswer":{"@type":"Answer","text":"As a clinical-stage biotechnology company, CU6 carries inherent speculative risk balanced against high potential reward. Investment suitability depends on an individual's risk tolerance, as its value is highly dependent on successful clinical trial outcomes, regulatory approvals, and eventual market adoption. It offers significant upside potential if its products succeed but also faces substantial risks typical of pre-revenue biotechs."}},{"@type":"Question","name":"What drives CU6's share price?","acceptedAnswer":{"@type":"Answer","text":"CU6's share price is primarily driven by news related to its clinical trials (e.g., positive or negative data readouts), regulatory milestones (e.g., FDA approvals), strategic partnerships, and capital raising activities. Broader sentiment towards the radiopharmaceutical and biotech sectors, as well as competitive developments, also play a role."}}]}6:["ticker","CU6","d"]
0:["Foe7ts1ISHdRr1MzWVj0J",[[["",{"children":["asx",{"children":[["ticker","CU6","d"],{"children":["__PAGE__?{\"ticker\":\"CU6\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","CU6","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Clarity Pharmaceuticals Ltd"," (","CU6",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Clarity Pharmaceuticals is an Australian radiopharmaceutical company focused on developing innovative diagnostic and therapeutic products for cancer using copper isotopes. Its proprietary 'Theranostics' platform targets cancers such as prostate cancer (with SAR-bisPSMA) and neuroblastoma (with SARTATE), with lead candidates currently in advanced global clinical trials."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$1.0B"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","$L3",null,{"ticker":"CU6"}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","Clarity Pharmaceuticals (CU6) operates as a pre-revenue, clinical-stage biotechnology company, deeply entrenched in the high-growth field of radiopharmaceuticals. The company's core technology leverages copper-64 for diagnostics and copper-67 for therapy, aiming to provide precision oncology solutions. Its primary programs, including Phase IIb and Phase III trials for SAR-bisPSMA in metastatic castrate-resistant prostate cancer and Phase II trials for SARTATE in neuroblastoma, represent significant R&D investment. As a company in the development phase, its financial profile is currently defined by substantial research expenditure and reliance on capital raises to fund ongoing clinical development.",{"children":"Clarity Pharmaceuticals (CU6) operates as a pre-revenue, clinical-stage biotechnology company, deeply entrenched in the high-growth field of radiopharmaceuticals. The company's core technology leverages copper-64 for diagnostics and copper-67 for therapy, aiming to provide precision oncology solutions. Its primary programs, including Phase IIb and Phase III trials for SAR-bisPSMA in metastatic castrate-resistant prostate cancer and Phase II trials for SARTATE in neuroblastoma, represent significant R&D investment. As a company in the development phase, its financial profile is currently defined by substantial research expenditure and reliance on capital raises to fund ongoing clinical development."}],["$","p","The growth outlook for CU6 is intrinsically linked to the successful progression and potential commercialisation of its clinical pipeline. Key catalysts for future share price appreciation include positive data readouts from its ongoing late-stage trials, particularly for SAR-bisPSMA, and subsequent regulatory approvals from major bodies like the U.S. FDA. Clarity's strategic direction involves establishing its 'Theranostics' platform as a leading approach in precision cancer treatment, expanding its intellectual property portfolio, and exploring potential strategic partnerships to accelerate market access and further pipeline development. Given its current market capitalization, CU6 remains a speculative investment highly dependent on clinical trial success and regulatory milestones.",{"children":"The growth outlook for CU6 is intrinsically linked to the successful progression and potential commercialisation of its clinical pipeline. Key catalysts for future share price appreciation include positive data readouts from its ongoing late-stage trials, particularly for SAR-bisPSMA, and subsequent regulatory approvals from major bodies like the U.S. FDA. Clarity's strategic direction involves establishing its 'Theranostics' platform as a leading approach in precision cancer treatment, expanding its intellectual property portfolio, and exploring potential strategic partnerships to accelerate market access and further pipeline development. Given its current market capitalization, CU6 remains a speculative investment highly dependent on clinical trial success and regulatory milestones."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Positive clinical trial results, particularly for SAR-bisPSMA in prostate cancer, leading to accelerated regulatory pathways and potential market approval.",{"children":["â€¢ ","Positive clinical trial results, particularly for SAR-bisPSMA in prostate cancer, leading to accelerated regulatory pathways and potential market approval."]}],["$","li","Securing major licensing or partnership agreements with larger pharmaceutical companies, validating its technology and providing non-dilutive funding for commercialisation.",{"children":["â€¢ ","Securing major licensing or partnership agreements with larger pharmaceutical companies, validating its technology and providing non-dilutive funding for commercialisation."]}],["$","li","Successful expansion of its pipeline into new cancer indications or further development of its existing programs, demonstrating broad applicability of its copper-based radiopharmaceuticals.",{"children":["â€¢ ","Successful expansion of its pipeline into new cancer indications or further development of its existing programs, demonstrating broad applicability of its copper-based radiopharmaceuticals."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Negative or inconclusive results from ongoing clinical trials, leading to significant delays, increased costs, or abandonment of key programs.",{"children":["â€¢ ","Negative or inconclusive results from ongoing clinical trials, leading to significant delays, increased costs, or abandonment of key programs."]}],["$","li","Regulatory setbacks or delays in obtaining approvals from health authorities (e.g., FDA, TGA), prolonging the time to market and increasing burn rate.",{"children":["â€¢ ","Regulatory setbacks or delays in obtaining approvals from health authorities (e.g., FDA, TGA), prolonging the time to market and increasing burn rate."]}],["$","li","Intense competition from established radiopharmaceutical companies or emerging alternative cancer therapies, potentially limiting market share upon commercialisation, or the necessity for further dilutive capital raises.",{"children":["â€¢ ","Intense competition from established radiopharmaceutical companies or emerging alternative cancer therapies, potentially limiting market share upon commercialisation, or the necessity for further dilutive capital raises."]}]]}]]}]]}]]}],null,["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Quarterly Activities/Appendix 4C Cash Flow Report"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"29 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Quarterly Report"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"The ASX announcement for Ticker: CU6, a Commitments Test Entity (CTE), details its quarterly cash flow activities and financial position in Appendix 4C of the Quarterly Reports. Investors are advised to review these figures closely as"}]]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"SECuRE trial to continue with no modifications to protocol"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"14 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Progress Report"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"Australian biotech firm Secure Therapeutics (ASX: CU6) confirms the continuation of its Phase II clinical trial for a novel Alzheimer'dementia treatment without any changes to the original study protocol."}]]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Notification of cessation of securities - CU6"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"7 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does CU6 do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does CU6 do?"}],["$","p",null,{"className":"text-slate-400","children":"Clarity Pharmaceuticals (CU6) is an Australian biotech company developing a new generation of diagnostic and therapeutic radiopharmaceuticals for cancer. They use copper isotopes (Copper-64 for imaging, Copper-67 for therapy) to target specific cancer cells, aiming for more precise and effective cancer treatment."}]]}],["$","div","Is CU6 a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is CU6 a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"As a clinical-stage biotechnology company, CU6 carries inherent speculative risk balanced against high potential reward. Investment suitability depends on an individual's risk tolerance, as its value is highly dependent on successful clinical trial outcomes, regulatory approvals, and eventual market adoption. It offers significant upside potential if its products succeed but also faces substantial risks typical of pre-revenue biotechs."}]]}],["$","div","What drives CU6's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives CU6's share price?"}],["$","p",null,{"className":"text-slate-400","children":"CU6's share price is primarily driven by news related to its clinical trials (e.g., positive or negative data readouts), regulatory milestones (e.g., FDA approvals), strategic partnerships, and capital raising activities. Broader sentiment towards the radiopharmaceutical and biotech sectors, as well as competitive developments, also play a role."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","2.89"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-emerald-400","children":["37.0","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$1.0B"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"25/08/2021"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Compare ASX Brokers"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Find the best trading platform for your needs. We review fees, features, and research tools."}],["$","div",null,{"className":"mt-4 grid gap-3 sm:grid-cols-2","children":[["$","div","AlphaTrade",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"AlphaTrade"}],["$","p",null,{"className":"text-xs text-slate-400","children":"$$0 brokerage on ETFs"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","MarketPilot",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"MarketPilot"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Advanced research suite"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Coastline",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Coastline"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Low FX fees"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Harbour",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Harbour"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Pro-level charting"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"Sponsored links. We may receive compensation if you open an account."}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L4",null,{"href":"/asx/CSL","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","181.24"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-27.3","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$88.2B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/PNV","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.99"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-13.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$670M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/1AD","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.01"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-25.6","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$11M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$6","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"grid-glow min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L4",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L8",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L4","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L4","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L4","/sectors/materials",{"href":"/sectors/materials","className":"transition hover:text-white","children":"Sectors"}],["$","$L4","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L4","/compare/BHP-vs-RIO",{"href":"/compare/BHP-vs-RIO","className":"transition hover:text-white","children":"Compare"}],["$","$L4","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 md:flex","children":[["$","$L9",null,{}],["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden","children":[["$","div",null,{"className":"flex-1","children":["$","$L9",null,{}]}],["$","$L4",null,{"href":"/screener","className":"shrink-0 text-xs text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L4",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/f5dc3b4b8467221e.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$La"]]]]]
a:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"CU6 share price, analysis & company profile - Clarity Pharmaceuticals Ltd | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest CU6 share price overview, what Clarity Pharmaceuticals Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/CU6/"}],["$","meta","5",{"property":"og:title","content":"CU6 share price, analysis & company profile - Clarity Pharmaceuticals Ltd"}],["$","meta","6",{"property":"og:description","content":"Latest CU6 share price overview, what Clarity Pharmaceuticals Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/CU6/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"CU6 share price, analysis & company profile - Clarity Pharmaceuticals Ltd"}],["$","meta","11",{"name":"twitter:description","content":"Latest CU6 share price overview, what Clarity Pharmaceuticals Ltd does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
